CorMedix (NASDAQ:CRMD) Price Target Cut to $14.00 by Analysts at Needham & Company LLC

CorMedix (NASDAQ:CRMD) had its price target lowered by Needham & Company LLC from $15.00 to $14.00 in a research note issued to investors on Thursday morning,Benzinga reports. The firm currently has a buy rating on the stock.

Other equities research analysts have also issued reports about the company. Zacks Research lowered CorMedix from a “hold” rating to a “strong sell” rating in a report on Tuesday, February 10th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of CorMedix in a research report on Wednesday, January 21st. Wall Street Zen downgraded shares of CorMedix from a “buy” rating to a “hold” rating in a research report on Saturday, November 15th. HC Wainwright dropped their price target on shares of CorMedix from $18.00 to $13.00 and set a “buy” rating on the stock in a research note on Friday, January 23rd. Finally, Truist Financial set a $16.00 price target on shares of CorMedix in a report on Thursday, January 8th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, CorMedix has an average rating of “Moderate Buy” and an average target price of $15.71.

CorMedix Stock Down 0.2%

Shares of CorMedix stock traded down $0.01 on Thursday, hitting $6.29. 324,407 shares of the company traded hands, compared to its average volume of 2,799,082. CorMedix has a 12-month low of $5.60 and a 12-month high of $17.43. The company has a quick ratio of 1.73, a current ratio of 1.94 and a debt-to-equity ratio of 0.39. The company has a market cap of $495.59 million, a PE ratio of 3.05 and a beta of 1.31. The company has a 50-day moving average price of $8.17 and a 200 day moving average price of $10.40.

CorMedix (NASDAQ:CRMD) last announced its quarterly earnings data on Thursday, March 5th. The company reported $0.16 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.86 by ($0.70). CorMedix had a return on equity of 51.77% and a net margin of 75.83%.The firm had revenue of $128.62 million for the quarter, compared to analysts’ expectations of $127.02 million. During the same quarter in the prior year, the business posted $0.22 earnings per share. CorMedix’s revenue was up 312.1% on a year-over-year basis. Sell-side analysts predict that CorMedix will post -0.32 earnings per share for the current year.

CorMedix declared that its Board of Directors has approved a stock repurchase plan on Monday, February 2nd that authorizes the company to buyback $75.00 million in outstanding shares. This buyback authorization authorizes the company to reacquire up to 12.3% of its stock through open market purchases. Stock buyback plans are usually an indication that the company’s leadership believes its stock is undervalued.

Insider Activity

In related news, CEO Joseph Todisco sold 30,000 shares of the firm’s stock in a transaction on Thursday, December 18th. The shares were sold at an average price of $12.00, for a total value of $360,000.00. Following the transaction, the chief executive officer directly owned 509,496 shares in the company, valued at approximately $6,113,952. This trade represents a 5.56% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Steven W. Lefkowitz sold 40,000 shares of CorMedix stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $11.88, for a total transaction of $475,200.00. Following the completion of the transaction, the director owned 80,498 shares in the company, valued at $956,316.24. This trade represents a 33.20% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 90,000 shares of company stock valued at $1,095,200 over the last 90 days. 3.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On CorMedix

Hedge funds and other institutional investors have recently made changes to their positions in the business. Ameritas Investment Partners Inc. lifted its position in shares of CorMedix by 17.9% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 6,562 shares of the company’s stock worth $81,000 after purchasing an additional 998 shares during the last quarter. Russell Investments Group Ltd. increased its position in CorMedix by 22.2% in the 2nd quarter. Russell Investments Group Ltd. now owns 6,553 shares of the company’s stock worth $81,000 after buying an additional 1,190 shares during the period. China Universal Asset Management Co. Ltd. lifted its holdings in shares of CorMedix by 11.9% during the second quarter. China Universal Asset Management Co. Ltd. now owns 13,622 shares of the company’s stock worth $168,000 after buying an additional 1,451 shares during the last quarter. Palisades Investment Partners LLC boosted its position in shares of CorMedix by 0.3% in the third quarter. Palisades Investment Partners LLC now owns 564,106 shares of the company’s stock valued at $6,561,000 after acquiring an additional 1,579 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of CorMedix by 4.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,987 shares of the company’s stock worth $222,000 after acquiring an additional 1,631 shares during the last quarter. 34.18% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting CorMedix

Here are the key news stories impacting CorMedix this week:

• Positive Sentiment: Needham cut its price target to $14 but kept a “buy” rating, signaling continued analyst conviction and implying material upside from current levels. Article Title
• Positive Sentiment: Analysts and coverage note that a planned buyback plus advancing REZZAYO clinical/commercial data could reduce float and create meaningful upside if upcoming results meet expectations. CorMedix Buyback And REZZAYO Data Shape Valuation And Risk Profile
• Positive Sentiment: Company reported strong Q4 net revenue ($128.6M) and pro forma full‑year 2025 net revenue of $401.3M, and provided a business update in its earnings release that investors may view as supportive of longer‑term growth. Press Release
• Neutral Sentiment: FY‑2026 revenue guidance was set to $300M–$320M versus a consensus near $309.5M — a range that brackets estimates and thus tempers clarity on near‑term upside, leaving room for interpretation. (Company guidance)
• Neutral Sentiment: Short‑interest reports in the news appear inconsistent or inconclusive (reported as 0 shares/NaN changes), so there’s no clear short‑squeeze signal driving moves.
• Negative Sentiment: EPS missed consensus materially (reported EPS below estimates), which is the primary driver of the stock weakness; coverage and transcripts note the earnings miss despite strong revenue growth. CRMD Lags Q4 Earnings Estimates
• Negative Sentiment: Market reaction: multiple outlets report the stock fell after the earnings miss and hit lows not seen in months — short‑term selling pressure reflects disappointment on EPS and uncertainty on near‑term catalysts. CorMedix stock falls after earnings miss

About CorMedix

CorMedix Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to reduce inflammation and prevent infection in critically and chronically ill patient populations. The company’s lead product candidate, Neutrolin, is a catheter lock solution that combines taurolidine, heparin and citrate to prevent catheter-related bloodstream infections (CRBSIs) in patients undergoing hemodialysis. Neutrolin has received market authorization in the European Union under the CE Mark and is positioned to address a significant unmet medical need for infection prevention in dialysis centers.

In addition to its lead asset, CorMedix is advancing a biochemical portfolio aimed at mitigating complications associated with peritoneal dialysis and other high-risk procedures.